ALTO-207 in Adults With Treatment-resistant Depression (TRD)
NCT07553637
This study is recruiting at 12 US sites in 9 states, according to its ClinicalTrials.gov record last updated .
Summary
The purpose of this trial is to measure depressive symptoms following treatment with ALTO-207 compared with placebo in participants with TRD.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Treatment-resistant Depression (TRD)
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 2
- Ages
- 18 to 75 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- Alto Neuroscience
- Last updated on ClinicalTrials.gov
- April 28, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
Arizona · 1
- Site 7000 · Phoenix, AZ
California · 2
- Site 7082 · Oceanside, CA
- Site 7144 · San Diego, CA
Florida · 1
- Site 7152 · Saint Augustine, FL
Georgia · 2
- Site 7148 · Albany, GA
- Site 7141 · Savannah, GA
Maryland · 1
- Site 7151 · Annapolis, MD
Michigan · 1
- Site 7154 · Bloomfield Hills, MI
North Carolina · 1
- Site 7143 · Charlotte, NC
Ohio · 1
- Site 7029 · Cincinnati, OH
Texas · 2
- Site 7145 · Houston, TX
- Site 7161 · Irving, TX
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.